The microbiome has been called the second human genome. It is shaped by how we were born, where we live and the foods and medicines we are given in childhood. In recent years, there has been an explosion in the number of scientific studies regarding the role of the gut microbiome in metabolic, allergic and autoimmune diseases. Therapeutic implications of altering the microbiome to alter disease states have taken shape and form an exciting new frontier of medicine.
This activity will use case-based scenarios to illustrate different patterns of liver test abnormalities. Dr. Han from the Dumont-UCLA Liver Transplant Center will discuss the difference between cholestatic versus hepatitis versus infiltrative liver diseases and their characteristic liver test patterns. Additionally, he will review the subsequent work-up of liver test abnormalities which are followed by supplemental serological testing, imaging, and in some cases, liver biopsy. He will also summarize the difference between true “liver function tests”, tests of cholestasis, tests of inflammation, and tests of infiltration.
Eosinophilic esophagitis (EoE) is a potentially serious inflammatory condition that can result in ED visits for food impaction and can severely impact quality of life for patients. Nirmala Gonsalves, MD, of Northwestern’s Fineberg School of Medicine reviews the symptoms, diagnosis, and treatment of EoE, and provides tips for long-term control of this condition.
This presentation will use case-based scenarios to illustrate different patterns of liver test abnormalities. The difference between cholestatic, hepatitis and infiltrative liver diseases and their characteristic liver test patterns will also be discussed.
This activity will provide a clinical approach to the management of non-alcoholic fatty liver disease (NAFLD), a highly prevalent condition. Dr. Balakrishnan will review the diagnosis and risk stratification of NAFLD and risk factors for liver disease progression, and will also provide an overview of existing and pipeline therapies. Most of the talk will focus on the most common form of NAFLD – which is associated with metabolic syndrome and insulin resistance. It will also expose the audience to less common forms of NAFLD to consider in the patient who is lean and/or does not have classic features of metabolic syndrome.
This activity provides an update on the diagnostic criteria for functional bowel disorders, including irritable bowel syndrome (IBS). The activity gives information on how to differentiate between IBS and other bowel disorders like microscopic colitis, celiac disease, colorectal cancer, and inflammatory bowel disease. It also discusses lifestyle and dietary interventions for managing IBS and includes a section on non-celiac gluten sensitivity and the FODMAP diet.
This program aims to review evidence based recommendations for managing non-alcoholic fatty liver disease as well as understand indications for biopsy and further investigation.
Apply new guidelines for the diagnosis of these digestive disorders, and recommend dietary adjustments as indicated.
Nonalcoholic fatty liver (NAFL) is an emerging concern among a subset of the diabetic and obese population. Complications arise when the disease progresses to nonalcoholic steatohepatitis (NASH) and cirrhosis. It is important for the primary care physician to recognize the hallmarks of NAFLD and the progression to NASH. Here, Dr. Chopra discusses strategies for diagnosis, treatment and management of patients with this hepatic disorder.
This activity will review the presenting features, diagnostic tests and management of patients with celiac disease. Dr. Leffler will discuss diagnostic problems and common issues that affect treatment and review the long term complications associated with celiac disease. He will also review available information on gluten sensitivity and discuss how the two disorders overlap.
In this activity, Dr. Damas will review the phenotypic manifestations and extra-intestinal manifestations of inflammatory bowel diseases, including Crohn’s and ulcerative colitis. She will explain what we currently know about disease pathogenesis, including the influence of genetics and the environment on the microbiome and finally, discuss some of the latest updates on treatment of IBD.
Irritable bowel syndrome (IBS) is the most common GI disorder seen in outpatient practice. Most patients with IBS do not receive a positive IBS diagnosis. While the underlying etiology remains unclear and probably multifactorial, there has been considerable progress in the understanding of this disease. This activity will review the recent theories about IBS and discuss them in relation to diagnosis and treatment. Dr. El-Serag will also review the recent medical and psychological treatments available for IBS.